UK Biotech Day 2026 | May 27-28 | London, UK

UK Biotech Day is a leading event for the UK life sciences sector, bringing together executives and R&D scientists from pharma, biotech, medtech, techbio, investors, lawyers, patent attorneys, CROs, CDMOs, accountants, bankers, executive search agencies, and more. Serving as a global gateway, the event connects the UK ecosystem with international partners to drive strategic collaborations…

BySaurabh ChaubeyMarch 30, 2026

PUBLICATIONS

THE IMPACT OF ARTIFICIAL INTELLIGENCE ON PHARMACEUTICAL AND LIFESCIENCES INDUSTRY

Abstract Just like the Internet in 1990’s, Artificial intelligence is now changing all aspects of our life and work. It’s impact is beginning to show in the industry and it is changing the life-sciences practice by fundamentally altering the way how medicines are discovered, developed, manufactured, approved, supplied and brought to market. In research and discovery, generative models and structure prediction systems shorten the path from target to lead and raise the ceiling…

ByRahul MittalMarch 24, 2026

INSIGHTS+

Key Biosimilars Events of February 2026

Shots: Regulatory momentum accelerated globally with multiple biosimilars securing key approvals and positive opinions, including Sandoz’s Enzeevu (Eylea biosimilar) in the US and Canada, Accord BioPharma’s Filkri (Neupogen biosimilar) US FDA approval, EC approvals for Gotenfia (Simponi biosimilar) and Ranluspec (Lucentis biosimilar), and CHMP positive opinions for tocilizumab and insulin biosimilars. Strategic partnerships expanded regional access as companies including Alvotech, Bio-Thera Solutions, Formycon,…

ByDipanshu DixitMarch 3, 2026

INSIGHTS+

2025 EMA Drug Approvals Outlook: A Year of Intentional, Biology Led Medicine Across Europe

Shots: EMA approvals in 2025 reinforce a biology-first regulatory standard, favoring mutation-exact, genotype-defined, and severity-weighted therapies that narrow indications, elevate rare diseases, and reward durability of benefit over rapid market expansion Convenience at the EMA is no longer cosmetic, it is integral to benefit–risk assessment, with oral, subcutaneous, and low-burden dosing strategies increasingly tied to adherence, long-term outcomes,…

ByDipanshu DixitJanuary 22, 2026

INSIGHTS+

EMA Marketing Authorization of New Drugs in December 2025

Shots: Innovation in drug development continues to reshape patient care across dermatology, cardiology, immunology, oncology, respiratory medicine, and infectious diseases, as regulatory momentum in Europe remains strong toward the end of 2025. Recent EMA actions highlight how advanced biologics, precision small molecules, and next-generation vaccines are translating clinical breakthroughs into real-world impact. In December 2025, the EMA…

ByDipanshu DixitJanuary 20, 2026

INSIGHTS+

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2025 (Part 02)

Shots: Novartis led biopharma dealmaking in 2025, executing 23 transactions worth $37.92B with a disciplined, high-impact strategy that balanced scale, science, and strategic fit Dealmaking was spread across high-conviction areas; neuroscience, cardiovascular disease, immunology, and RNA platforms, combining transformational acquisitions with flexible licensing partnerships to build a future-ready pipeline Standout transactions (Avidity, Monte…

ByPrince GiriJanuary 16, 2026

VIEWPOINTS

Evorpacept’s Momentum in HER2+ Gastric Cancer: A Conversation with Jason Lettmann from ALX Oncology

Shots: Evorpacept emerges as the only CD47-blocking therapy with strong clinical activity and a highly manageable safety profile, thanks to its unique inactive Fc design that enables targeted tumor destruction while sparing healthy cells Updated ASPEN-06 data highlights CD47 overexpression as a powerful predictive biomarker, showing dramatic improvements in ORR, DOR, PFS, and OS for patients with…

BySaurabh ChaubeyDecember 3, 2025

NEWS

Merck to Acquire Cidara Therapeutics for ~$9.2B to Bolster Antiviral Pipeline

Shots: Merck has signed a definitive agreement to acquire Cidara Therapeutics through a subsidiary, adding the company’s lead late-stage antiviral candidate CD388 to its pipeline Merck will acquire Cidara at $221.50 per share in cash, valuing the deal at approximately $9.2B. The transaction is expected to close in Q1’26 Cidara’s CD388 (currently in P-III) is…

ByRidhi RastogiNovember 17, 2025

NEWS

Metsera Announces an Amended Merger Agreement with Pfizer for ~$10B

Shots: Metsera announced entering into an amended merger agreement with Pfizer to acquire Metsera for up to $86.25 per share, including $65.60 in cash and a contingent value right of up to $20.65 Metsera’s Board of Directors noted that the U.S. Federal Trade Commission had raised potential antitrust concerns regarding Novo Nordisk’s proposed structure After…

BySaurabh ChaubeyNovember 8, 2025

INSIGHTS+

Know Your Investor: Samsara Biocapital (November’25 Edition)

Shots: Samsara Biocapital is a California-based venture capital and registered investment adviser investing across early to post-IPO stages in healthcare, life sciences, oncology, and digital health, with a portfolio of 70+ companies including Scholar Rock and PepGen The firm made 30 investments across PIPE (43%), Series B (23%), and other rounds, with notable deals such…

ByPrince GiriNovember 5, 2025

UK Biotech Day 2026 | May 27-28 | London, UK

THE IMPACT OF ARTIFICIAL INTELLIGENCE ON PHARMACEUTICAL AND LIFESCIENCES INDUSTRY

Key Biosimilars Events of February 2026

2025 EMA Drug Approvals Outlook: A Year of Intentional, Biology Led Medicine Across Europe

EMA Marketing Authorization of New Drugs in December 2025

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2025 (Part 02)

Evorpacept’s Momentum in HER2+ Gastric Cancer: A Conversation with Jason Lettmann from ALX Oncology

Merck to Acquire Cidara Therapeutics for ~$9.2B to Bolster Antiviral Pipeline

Metsera Announces an Amended Merger Agreement with Pfizer for ~$10B

Know Your Investor: Samsara Biocapital (November’25 Edition)

Contact US

FOLLOW US